Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:EDITNASDAQ:NTLANYSE:NVSNASDAQ:REGNNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$52.16+0.9%$40.68$30.04▼$63.68$4.51B1.821.89 million shs1.84 million shsEDITEditas Medicine$2.59+1.0%$1.85$0.91▼$6.05$215.14M2.152.61 million shs1.91 million shsNTLAIntellia Therapeutics$10.72-0.1%$8.77$5.90▼$28.18$1.11B2.212.97 million shs2.81 million shsNVSNovartis$121.90-1.5%$115.08$96.06▼$124.45$257.50B0.591.59 million shs955,240 shsREGNRegeneron Pharmaceuticals$545.00-0.5%$549.38$476.49▼$1,211.20$59.10B0.33905,431 shs456,413 shsVRTXVertex Pharmaceuticals$454.64-0.5%$450.84$377.85▼$519.88$118.03B0.411.42 million shs763,957 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+9.82%+37.07%+59.74%-3.24%EDITEditas Medicine0.00%+13.38%+42.03%+150.97%-44.53%NTLAIntellia Therapeutics0.00%+12.08%+39.70%+61.61%-53.31%NVSNovartis0.00%+1.33%+4.11%+15.23%+14.16%REGNRegeneron Pharmaceuticals0.00%+4.61%+12.39%-4.96%-46.78%VRTXVertex Pharmaceuticals0.00%+3.02%+1.97%-4.21%-3.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.0212 of 5 stars4.31.00.00.02.02.50.6EDITEditas Medicine4.2085 of 5 stars3.23.00.04.32.02.50.6NTLAIntellia Therapeutics4.7207 of 5 stars4.33.00.04.72.12.50.6NVSNovartis1.6626 of 5 stars1.03.02.50.02.70.01.9REGNRegeneron Pharmaceuticals4.9558 of 5 stars4.45.01.72.33.31.71.9VRTXVertex Pharmaceuticals4.7258 of 5 stars3.35.00.03.33.42.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7537.57% UpsideEDITEditas Medicine 2.31Hold$4.7081.82% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37211.42% UpsideNVSNovartis 2.00Hold$123.671.45% UpsideREGNRegeneron Pharmaceuticals 2.80Moderate Buy$813.5749.28% UpsideVRTXVertex Pharmaceuticals 2.54Moderate Buy$511.6212.53% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025REGNRegeneron PharmaceuticalsArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/23/2025VRTXVertex PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$550.006/20/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.006/17/2025VRTXVertex PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.006/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M120.72N/AN/A$22.64 per share2.30EDITEditas Medicine$32.31M6.70N/AN/A$1.63 per share1.59NTLAIntellia Therapeutics$57.88M19.18N/AN/A$8.56 per share1.25NVSNovartis$50.32B5.12$10.70 per share11.39$21.59 per share5.65REGNRegeneron Pharmaceuticals$14.20B4.14$45.49 per share11.98$268.50 per share2.03VRTXVertex Pharmaceuticals$11.02B10.59N/AN/A$63.72 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)NVSNovartis$11.94B$6.4019.0513.841.6824.70%39.44%16.43%7/17/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2813.8714.332.0031.94%15.27%11.93%8/1/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A25.96N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)Latest EDIT, NTLA, VRTX, CRSP, NVS, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.53N/AN/AN/A$3.30 billionN/A7/17/2025Q2 2025NVSNovartis$2.37N/AN/AN/A$13.94 billionN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$2.602.13%N/A40.63%N/AREGNRegeneron Pharmaceuticals$3.520.65%N/A8.96%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64EDITEditas MedicineN/A3.083.08NTLAIntellia TherapeuticsN/A4.904.90NVSNovartis0.560.790.61REGNRegeneron Pharmaceuticals0.094.934.03VRTXVertex Pharmaceuticals0.012.652.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%EDITEditas Medicine71.90%NTLAIntellia Therapeutics88.77%NVSNovartis13.12%REGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%EDITEditas Medicine2.10%NTLAIntellia Therapeutics3.10%NVSNovartis0.01%REGNRegeneron Pharmaceuticals7.02%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46086.36 million82.65 millionOptionableEDITEditas Medicine23083.71 million81.96 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableVRTXVertex Pharmaceuticals6,100256.80 million256.28 millionOptionableEDIT, NTLA, VRTX, CRSP, NVS, and REGN HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Cut by Braun Stacey Associates Inc.July 5 at 8:41 AM | marketbeat.comHM Payson & Co. Has $2.82 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 5 at 8:33 AM | marketbeat.comThe Best Stocks to Invest $1,000 In Right NowJuly 5 at 4:51 AM | fool.comKintegral Advisory LLC Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 4 at 8:38 AM | marketbeat.comIFM Investors Pty Ltd Purchases 4,691 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 4 at 8:04 AM | marketbeat.comGF Fund Management CO. LTD. Has $29.48 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 4 at 8:02 AM | marketbeat.comPrincipal Financial Group Inc. Grows Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 4 at 5:56 AM | marketbeat.comFirst Horizon Advisors Inc. Purchases 17,116 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 4 at 5:26 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Highlights Long-Term Benefits of Gene TherapyJuly 3 at 2:10 PM | gurufocus.comMeritage Portfolio Management Sells 862 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 3 at 8:06 AM | marketbeat.comZWJ Investment Counsel Inc. Has $1.83 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 3 at 7:56 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Teacher Retirement System of TexasJuly 3 at 7:29 AM | marketbeat.comPinnacle Financial Partners Inc Acquires 3,158 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 3 at 6:09 AM | marketbeat.comVertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment AccessJuly 2 at 2:45 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowJuly 2 at 10:00 AM | zacks.comEU approves Vertex's next-generation cystic fibrosis drugJuly 2 at 9:43 AM | msn.comVertex Gets EU Nod for New Cystic Fibrosis Drug AlyftrekJuly 2 at 9:35 AM | zacks.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by WCM Investment Management LLCJuly 2 at 8:25 AM | marketbeat.comWASHINGTON TRUST Co Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 2 at 5:25 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key FactsJuly 1, 2025 | zacks.comVRTX - Vertex Pharmaceuticals Inc Dividends - MorningstarJuly 1, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeCapitalize on Volatility: 3 Finance Stocks Thriving in 2025By Chris Markoch | July 2, 2025View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025EDIT, NTLA, VRTX, CRSP, NVS, and REGN Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$52.16 +0.49 (+0.94%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$52.16 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Editas Medicine NASDAQ:EDIT$2.58 +0.03 (+0.98%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$2.60 +0.01 (+0.39%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$10.72 -0.02 (-0.14%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$10.66 -0.06 (-0.56%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$121.90 -1.91 (-1.54%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$123.50 +1.60 (+1.32%) As of 07/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Regeneron Pharmaceuticals NASDAQ:REGN$545.00 -2.74 (-0.50%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$547.81 +2.81 (+0.52%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$454.64 -2.40 (-0.52%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$454.64 0.00 (0.00%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
